Home › Research › Treatments
Nose to Brain Delivery of Curcumin Loaded Therapeutic Nanostructures for Neurodegenerative Diseases
Rupsikha Kalita, Anupam Sarma, Himakshi Baruah, Asifa Zaman, Deepjyoti Goswami. Biopharmaceutics & Drug Disposition, 2026-01-03
Topic: Brain proteins, microglia and lab models
Plain-language summary
Neurodegenerative diseases are progressive disorders that damage and eventually kill neurons in the central nervous system (CNS). In recent years, various research has been done on reliable and effective treatment methods for the most common neurodegenerative diseases such as Parkinson's, Alzheimer, and Migraine diseases. Different neurodegenerative disorders such as Huntington's disease, Alzheimer's disease, Parkinson's disease, amyotrophic, Lewy body disease can be treated by curcumin, which is a strong antioxidant polyphenol with neuroprotective and anti-amyloid properties. However, Blood-brain barrier (BBB) and blood cerebrospinal fluid barrier restricts the permeation of curcumin to the brain leads poor distribution of the drug in brain tissue. The intranasal pathway holds promise for enhancing the treatment of CNS disorders since it bypasses the BBB and increases the brain bioavailability of drug. As nanotechnology continues to improve, research on the delivery of drug through intranasal route has grown significantly in last 10 years. Several nanocarriers have been developed such as nano-emulsions, microspheres, dendrimers, liposomes, carbon-based nanoformulation, and nanoparticles to deliver curcumin to the brain via intranasal route for the treatment of neurodegenerative diseases. This study provided a thorough analysis of several curcumin nano-formulations used in intranasal pathway as a novel treatment for neurodegenerative diseases.
What this study adds
Evidence grade: Low
This review examines curcumin-loaded nanostructures delivered through the nose to bypass the blood-brain barrier and increase curcumin's availability in the brain for neurodegenerative diseases. It is a review of delivery approaches, not a clinical trial, so no conclusions about treating or preventing Alzheimer's disease in patients can be drawn from it.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kalita, R., Sarma, A., Baruah, H., Zaman, A., & Goswami, D. (2026). Nose to Brain Delivery of Curcumin Loaded Therapeutic Nanostructures for Neurodegenerative Diseases. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.70021
Vancouver
Kalita R, Sarma A, Baruah H, Zaman A, Goswami D. Nose to Brain Delivery of Curcumin Loaded Therapeutic Nanostructures for Neurodegenerative Diseases. Biopharmaceutics & Drug Disposition. 2026. doi:10.1002/bdd.70021. PMID: 41482856.
BibTeX
@article{kalita2026-41482856,
author = {Kalita, Rupsikha and Sarma, Anupam and Baruah, Himakshi and Zaman, Asifa and Goswami, Deepjyoti},
title = {{Nose to Brain Delivery of Curcumin Loaded Therapeutic Nanostructures for Neurodegenerative Diseases}},
journal = {Biopharmaceutics \& Drug Disposition},
year = {2026},
doi = {10.1002/bdd.70021},
pmid = {41482856},
url = {https://doi.org/10.1002/bdd.70021}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- As nanotechnology continues to improve, research on the delivery of drug through intranasal route has grown significantly in last 10 years.
Why it matters
This review examines curcumin-loaded nanostructures delivered through the nose to bypass the blood-brain barrier and increase curcumin's availability in the brain for neurodegenerative diseases. It is a review of delivery approaches, not a clinical trial, so no conclusions about treating or preventing Alzheimer's disease in patients can be drawn from it.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 31/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 30 of the 96 points we could judge it on, which is 31 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Biopharmaceutics & Drug Disposition) |
| Journal's citation record | 1 / 4 | Biopharmaceutics & Drug Disposition: journal h-index 79 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 3.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Deepjyoti Goswami holds only 2 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Dibrugarh University: institution h-index 115 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41482856) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 30 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 30 of the 96 points we could judge it on is 31 out of 100. |
| Total | 31 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.